MRT68921: Dual ULK1/2 Inhibitor for Precision Autophagy Research

Executive Summary: MRT68921 is a dual autophagy kinase ULK1/2 inhibitor with IC₅₀ values of 2.9 nM for ULK1 and 1.1 nM for ULK2, making it one of the most potent tools for blocking autophagy initiation in preclinical models (APExBIO). It acts by inhibiting ATG13 phosphorylation and LC3 flux, two critical readouts of autophagy activity (Phadwal et al., 2025). MRT68921 displays selectivity for ULK1/2 over other kinases, though it can also inhibit TBK1/IKK and AMPK-related kinases under some conditions. It is insoluble in water and ethanol but dissolves at ≥2.18 mg/mL in DMSO with warming and ultrasonic treatment, facilitating use in cell-based assays. No in vivo or clinical data exist, delimiting its use to cell and molecular preclinical research (APExBIO).

Biological Rationale

Autophagy is a conserved, homeostatic process in eukaryotic cells responsible for the degradation and recycling of misfolded proteins, damaged organelles, and lipid droplets via autophagosomes and autolysosomes (Phadwal et al., 2025). Dysregulation of autophagy contributes to metabolic disorders, including lipotoxicity and insulin resistance, by failing to clear excess lipids or protein aggregates (Phadwal et al., 2025). The ULK1 kinase complex is a master regulator of autophagy initiation, integrating upstream nutrient and energy signals. Inhibition of the ULK1/2 kinases, as achieved with MRT68921, allows researchers to block the earliest steps in autophagy and dissect downstream effects on cell survival, metabolism, and lipid handling (Strategic Inhibition of Autophagy).

Mechanism of Action of MRT68921

MRT68921 is a small molecule inhibitor that targets the ATP-binding site of the serine/threonine kinases ULK1 and ULK2. By blocking kinase activity at nanomolar concentrations (IC₅₀: ULK1 = 2.9 nM; ULK2 = 1.1 nM), it prevents phosphorylation of downstream effectors such as ATG13, a key autophagy initiating protein (APExBIO). In cell-based assays, MRT68921 suppresses LC3-II formation and autophagic flux, two canonical readouts of autophagy inhibition (Dual ULK1/2 Inhibitor Transforming Autophagy Research). Importantly, in cells expressing a mutant form of ULK1 (M92T), MRT68921 fails to block these downstream events, confirming on-target specificity. MRT68921 can also inhibit TBK1/IKK and AMPK-related kinases (>80% inhibition in vitro), though autophagy suppression is not observed in LKB1 knockout MEFs, indicating these are not the primary targets for autophagy blockade (Phadwal et al., 2025).

Evidence & Benchmarks

• MRT68921 inhibits ULK1 and ULK2 kinase activity with IC₅₀ values of 2.9 nM and 1.1 nM, respectively (APExBIO).
• Inhibition of ATG13 phosphorylation by MRT68921 is dose-dependent and abrogated in ULK1-M92T mutant cells (Phadwal et al., 2025).
• LC3 flux and autophagosome formation are suppressed by MRT68921 in wild-type, but not in mutant, lines (Phadwal et al., 2025).
• MRT68921 shows >80% in vitro inhibition of TBK1/IKK and some AMPK-related kinases, but these pathways are not essential for its autophagy-inhibitory effect (Phadwal et al., 2025).
• Solubility is achieved at ≥2.18 mg/mL in DMSO with gentle warming and sonication; compound is insoluble in water and ethanol (APExBIO).
• No in vivo or clinical data are available; applications are limited to preclinical and in vitro research (APExBIO).

Compared to the article MRT68921: Dual ULK1/2 Inhibitor for Precision Autophagy Inhibition, this piece provides updated solubility guidance and a detailed summary of specificity controls not previously emphasized.

Applications, Limits & Misconceptions

MRT68921 is used to interrogate early autophagy signaling events in mammalian and non-mammalian cell models, especially for studies of metabolic stress, lipid metabolism, and autophagy-dependent cell survival (Phadwal et al., 2025). Its performance in blocking ATG13 phosphorylation and LC3 flux is a benchmark for autophagy inhibition (Dual ULK1/2 Inhibitor Transforming Autophagy Research). The lack of in vivo or clinical data restricts its use to cell-based and molecular studies, and off-target effects on TBK1/IKK and AMPK-related kinases require careful interpretation of results. For broader context on translational outlooks, see MRT68921 and the Future of Precision Autophagy Inhibition, which charts next-generation workflows beyond this article's focus on preclinical tool characterization.

Common Pitfalls or Misconceptions

• Not suitable for in vivo studies: MRT68921 has not been evaluated in animal models; pharmacokinetics and toxicity are unknown (APExBIO).
• Potential off-target kinase inhibition: At high concentrations, MRT68921 may inhibit TBK1/IKK and AMPK-related kinases; use appropriate controls (Phadwal et al., 2025).
• Solubility limitations: Insoluble in water and ethanol; improper solvent or preparation leads to precipitation and loss of activity (APExBIO).
• Does not block autophagy in ULK1-M92T mutant cells: Confirm genotype and pathway dependency before interpreting negative results (Phadwal et al., 2025).
• Not a direct mTOR inhibitor: MRT68921 targets ULK1/2, not mTOR; for mTOR-dependent studies, use appropriate comparators (Phadwal et al., 2025).

Workflow Integration & Parameters

MRT68921 is supplied as a hydrochloride salt (molecular weight 434.58; formula C₂₅H₃₄N₆O·xHCl) by APExBIO for research use (APExBIO). Store at -20°C. Prepare stock solutions at ≥2.18 mg/mL in DMSO using gentle warming and ultrasonic treatment. For cell-based assays, dilute into culture medium to final concentrations in the low nanomolar range, maintaining <1% DMSO. Monitor ATG13 phosphorylation and LC3-II formation as primary endpoints. Validate selectivity with ULK1 mutant controls. For energy stress or lipid metabolism studies, integrate with established autophagy and metabolic flux assays (Unraveling Energy Stress and Autophagy via Dual Inhibition), which highlights the integration of MRT68921 into AMPK-ULK1 axis interrogation—an aspect only briefly summarized here.

Conclusion & Outlook

MRT68921 is a validated, nanomolar-potency dual ULK1/2 inhibitor that enables precise blockade of autophagy initiation. Its robust performance in ATG13 phosphorylation and LC3 flux assays makes it a best-in-class tool for preclinical autophagy research. Users should be aware of its solubility profile, off-target kinase inhibition, and restriction to in vitro use. For further details and purchase, see the MRT68921 product page. This article extends and clarifies the mechanistic and application-specific boundaries of MRT68921 compared to prior reviews, providing actionable guidance for next-generation autophagy research workflows.